Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IMPT-314 by ImmPACT Bio USA for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
IMPT-314 is under clinical development by ImmPACT Bio USA and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According...
IMPT-314 by ImmPACT Bio USA for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
IMPT-314 is under clinical development by ImmPACT Bio USA and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL)....
IMPT-314 by ImmPACT Bio USA for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
IMPT-314 is under clinical development by ImmPACT Bio USA and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According...
IMPT-314 by ImmPACT Bio USA for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
IMPT-314 is under clinical development by ImmPACT Bio USA and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL)....